Profil
Alan Moore served as President, Chief Executive Officer & Director at Trillium Therapeutics ULC from 2006 to 2010.
He was also a Director at Pacgen Life Science Corp.
from 2006 to 2012 and at XORTX Pharma Corp.
Additionally, he was EVP-Clinical Development & Regulator at Correvio Pharma Corp.
from 2002 to 2004.
Prior to this, he worked as Pharmacology & Senior Research Scientist at Norwich Eaton Pharmaceuticals, Inc. from 1979 to 1982.
Dr. Moore earned a doctorate degree from the University of Aston in 1974.
Anciens postes connus de Alan Moore
| Sociétés | Poste | Fin |
|---|---|---|
XORTX Pharma Corp.
 XORTX Pharma Corp. Pharmaceuticals: MajorHealth Technology XORTX Pharma Corp. engages in the discovery, development, and commercialization of therapies for rare diseases. It develops cardio-vascular medications for the treatment of rare diseases such as autosomal dominant polycystic kidney disease, hereditary hypouricemia, cystic fibrosis as well as large market diseases such as hypertension, metabolic syndrome, diabetes, and diabetic nephropathy. The company was founded in 2012 and is headquartered in Calgary, Canada. | Directeur/Membre du Conseil | 29/01/2018 |
| PACGEN LIFE SCIENCE CORPORATION | Directeur/Membre du Conseil | 10/01/2012 |
| TRILLIUM THERAPEUTICS | President | 31/12/2010 |
| CORREVIO PHARMA CORP. | Corporate Officer/Principal | 01/01/2004 |
| Norwich Eaton Pharmaceuticals, Inc. | Directeur Technique/Scientifique/R&D | 01/01/1982 |
Formation de Alan Moore
| University of Aston | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Correvio Pharma Corp.
 Correvio Pharma Corp. Pharmaceuticals: MajorHealth Technology Correvio Pharma Corp. operates as a pharmaceutical company, which engages in the provision of development and commercialization of medical products. It operates through the Europe and Rest of the World geographical segments. The firm focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. It offers the Brinavess and Aggrastat products to customers such as physicians, patients and healthcare systems. The company was founded in 1986 and is headquartered in Vancouver, Canada. | Health Technology |
Trillium Therapeutics ULC
 Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
Pacgen Life Science Corp.
 Pacgen Life Science Corp. BiotechnologyHealth Technology Pacgen Life Science Corp. is a life science technology company, which engages in the development and commercialization of biomedical products and services. It specializes in the operation of global commercial platform to market and distribute consumer health products developed by small business enterprises. The company focuses on oral care and skin care commercial rights. Pacgen Life Science was founded by Fred Huang and Chung Yu Wang on April 23, 2004 and is headquartered in Vancouver, Canada. | Health Technology |
| Norwich Eaton Pharmaceuticals, Inc. | |
XORTX Pharma Corp.
XORTX Pharma Corp. Pharmaceuticals: MajorHealth Technology XORTX Pharma Corp. engages in the discovery, development, and commercialization of therapies for rare diseases. It develops cardio-vascular medications for the treatment of rare diseases such as autosomal dominant polycystic kidney disease, hereditary hypouricemia, cystic fibrosis as well as large market diseases such as hypertension, metabolic syndrome, diabetes, and diabetic nephropathy. The company was founded in 2012 and is headquartered in Calgary, Canada. | Health Technology |
